Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India. The AIM-traded firm said the newly-granted patent in India encompassed both the composition of matter patent for the Nuvec particle itself, and the associated manufacturing process.

It said the achievement aligned with previously-granted patents in various regions, including the US, Canada, Europe, Japan, Australia and China.

"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec," said chief executive officer Nigel Theobald.

At 1111 GMT, shares in N4 Pharma were up 3.09% at 1p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Apollo to buy IGT Gaming and Everi in $6.3bn deal
(Sharecast News) - Apollo Global Management has agreed to buy International Game Technology's gaming and digital business - IGT Gaming - and gambling machines firm Everi Holdings in a $6.3bn cash deal.
3M comfortably beats expectations for Q2 revenue, earnings
(Sharecast News) - American industrial conglomerate 3M announced a strong set of second-quarter results on Friday, comfortably beating market expectations as it narrowed its guidance for the full-year towards the top end of its previous expectations.
Law Debenture delivers 'solid' overall first-half performance
(Sharecast News) - Law Debenture Corporation reported a robust first-half performance in both its investment and independent professional services (IPS) business on Friday.
GCP Infrastructure reports slight decrease in NAV per share
(Sharecast News) - GCP Infrastructure Investments said in an update on Friday that its unaudited net asset value per share was 107.58p as at 30 June, a slight decrease from 107.62p at the end of March.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.